A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the minimum dose of abiraterone acetate needed to
decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid
replacement for classic 21-hydroxylase deficiency.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.